Colchicine
Inhibits neutrophil chemotaxis and microtubule assembly
- Response rate
- Variable; partial responses reported
- Onset
- Days–weeks
- Route
- Oral 0.6-1.2 mg daily
- Line
- 1st
- IgM effect
- Minimal complement effect
Evidence summary
Used as first-line therapy for mild cutaneous UV with arthralgias. Inhibits neutrophil migration to vessel walls, addressing the leukocytoclastic vasculitis. Often used in combination with hydroxychloroquine and dapsone.